NEW YORK (GenomeWeb) – Genomic Health officials said this week that changes are in the works for the report the company returns to physicians as part of its Oncotype DX prostate cancer risk test.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.